Parexel recruits NextDocs to its stable of eClinical collaborators

NextDocs, a venture-backed document-management company, has signed a deal with Parexel ($PRXL) to integrate its services with the CRO's growing eClinical platform.

Under the agreement, NextDocs has joined the Parexel Perceptive Partner Program, through which the two companies will co-market their technologies. NextDocs brings its electronic trial master file offering--currently managing more than 1 million regulatory documents for sponsors and CROs--which Parexel will weave in with its own trial management system and regulatory software.

The idea is to offer mutual clients a seamless way to integrate data from disparate platforms, the companies said.

"Integration between clinical trial management solutions and comprehensive eClinical platforms such as Perceptive MyTrials is considered a paramount requirement for the industry and our customer base," NextDocs Vice President Ephraim Peak. "Alignment with Parexel Informatics positions NextDocs to deliver that promise to our customers."

For NextDocs, the deal follows a string of high-profile partnerships, as the company has aligned itself with Microsoft ($MSFT) and BioClinica on the way to building a customer base that includes AstraZeneca ($AZN), Sanofi ($SNY) and Novartis ($NVS).

Parexel's eClinical business, which dropped its former "Perceptive" moniker and took on the company name in February, has been its most reliable growth engine. The CRO's traditional drug development units have mostly ebbed and flowed with market trends, but its eClinical segment has long been a steady source of revenue growth. In the fiscal year ended June 30, the business brought in $267.9 million, a 17% jump over 2013.

- read the statement

Suggested Articles

The platform uses wearables to continuously collect clinical data from study participants and applies machine learning to analyze the data.

St. Jude, Microsoft and DNAnexus have created a data-sharing and analysis platform to help accelerate pediatric cancer research.

Charles River partners with PathoQuest to offer clients NGS solutions for biologics viral contamination testing and cell-line genetic characterization.